Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Barr Pharmaceuticals confirms patent challenge of Namenda tablets

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Forest Laboratories, Inc. in connection with its Namenda (memantine hydrochloride) tablets, 5mg and 10mg.

14 Jan 2008

Barr Pharmaceuticals confirms Eloxatin injectable patent challenge

Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, has initiated a challenge of the patents listed by Sanofi-Aventis U.S. LLC in connection with its Eloxatin(R) (Oxaliplatin Aqueous Solution), 5mg/mL Injectable.

10 Jan 2008

Study proves the co-pay connection in chronic disease

As 2008 begins, millions of Americans are having to dig deeper into their own pockets every time they refill a prescription or see a doctor.

9 Jan 2008

A look at China's most innovative health biotechnology companies

Government funds innovation but venture capital needed; Wary investors 'need to be shown the exits'; Returning 'sea turtles' bring expertise, international credibility

8 Jan 2008

Watson Pharmaceuticals launches generic Biaxin

Watson Pharmaceuticals, Inc. has announced it has launched Clarithromycin Extended-Release Tablets, USP in the 500 mg strength.

4 Jan 2008

Watson receives FDA approval for generic DuoNeb

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced today that it has received final approval from the United States (U.S.).

3 Jan 2008

Avoiding overuse, misuse, and underuse of medications

Adverse drug events are more common in older adults because they are prescribed more drugs and are effected differently by these drugs than their younger counterparts.

3 Jan 2008

Barr receives approval for generic KYTRIL tablets

Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Roche Laboratories Inc.'s KYTRIL (granisetron hydrochloride) Tablets, 1mg (eq to 1 mg base).

3 Jan 2008

Mylan announces FDA approval for Cetirizine Hydrochloride tablets

Mylan Inc. has announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets (OTC), 5 mg and 10 mg.

2 Jan 2008

Barr sues Watson and Sandoz for Seasonale patent infringement

Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its wholly-owned subsidiary, Duramed Pharmaceuticals, Inc. has filed suits against Watson Pharmaceuticals (NYSE:WPI) and against Sandoz, a subsidiary of Novartis (NYSE:NVS) for infringement of the patent protecting Duramed's SEASONALE(R) extended-cycle oral contraceptive product.

17 Dec 2007

Carbamazepine based drugs to include new advice for patients with Asian ancestry

The U.S. Food and Drug Administration today announced that the manufacturers of drugs containing the active ingredient carbamazepine have agreed to add to the drugs' labeling a recommendation that, before starting therapy with the drugs, patients with Asian ancestry get a genetic blood test that can identify a significantly increased risk of developing a rare, but serious, skin reaction.

13 Dec 2007

Caraco Pharmaceutical Labs announces FDA approval to market generic Norvasc

Caraco Pharmaceutical Laboratories has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg (Amlodipine).

5 Dec 2007

Health professionals worry about ethnic sensitivity

Health professionals worry that a lack of knowledge about different cultures may lead to them being seen as insensitive or inappropriate to patients from different ethnic backgrounds - according to new research.

29 Nov 2007

Watson Pharmaceuticals receives FDA approval for generic Combunox

Watson Pharmaceuticals, Inc. has announced that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride and Ibuprofen Tablets (CII) in the 5 mg/400 mg strength.

27 Nov 2007

Barr Pharmaceuticals confirms patent challenge of Focalin XR

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed for Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules, 5mg, 10mg, 15mg & 20mg. Focalin XR is manufactured for the U.S. for Novartis Pharmaceuticals Corporation by Elan Holdings Inc.

21 Nov 2007

Medics worry about ethnic sensitivity

14 Nov 2007

Brazilian experience of AIDS cocktails

AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as “AIDS cocktails.”

13 Nov 2007

75% of Medicare beneficiaries with stand-alone prescription drug plans could face premium increases in 2008

The open enrollment period for the Medicare Part D prescription drug benefit begins Thursday and continues through the end of the year, and beneficiaries should "look closely" at their plans because many of them are increasing premiums, copayments and deductibles, the Baltimore Sun reports.

12 Nov 2007

Barr confirms patent challenge of Ritalin LA

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Novartis Pharmaceuticals Corporation in connection with its Ritalin LA (methylphenidate hydrochloride) extended-release capsules, 10mg, 20mg, 30mg and 40mg.

5 Nov 2007

Mylan settles Paroxetine Hydrochloride patent license with GlaxoSmithKline

Mylan Inc. has announced that it and its subsidiary Mylan Pharmaceuticals Inc. have entered into a patent license and settlement agreement with GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, the generic version of GSK's Paxil CR.

24 Oct 2007